A PHASE 1/2, MULTICENTER, OPEN-LABEL, STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN, AND EVALUATE THE SAFETY AND PRELIMINARY EFFICACY OF CC-92480 IN COMBINATION WITH STANDARD TREATMENTS IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) AND NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)
NOT ENROLLING
Trial ID:
NCT03989414 Protocol # :
19-389
Phase
I/II
Disease Sites
Multiple Myeloma
Principal Investigator
Richardson, Paul, G
Site Investigator
Raje, Noopur
Rosenblatt, Jacalyn
Site Research Nurses
Babcock, Elise
Bright, Susan
Gammon, Marilyn
Knudsen, Elisabeth
Lively, Kathleen, J.
Marzullo, Tess, V.
Nutter, Meredith, Elise
Smith, Caitlin
Trial Description
Call 877-DF-TRIAL (877-338-7425) to learn more about this clinical trial, protocol #19-389
19-389